Technology | Population Health | April 23, 2015

Philips Introduces Predictive Analytics for Population Health Management

CareSage combines actionable insights with wearable medical alert devices to help reduce avoidable hospitalizations of elderly patients, keeping them at home and independent

April 23, 2015 — Philips introduced CareSage at HIMSS 2015, which is new predictive analytics engine that enables health systems to better monitor and care for elderly patients by combining actionable insights with wearable devices and monitoring. CareSage provides analysis of real-time and historical data from health care providers and Philips Lifeline, to proactively identify patients most likely to have health issues so clinicians can intervene before problems occur, helping patients stay healthier and reduce avoidable hospitalizations.

CareSage is the latest innovation being built on the Philips HealthSuite Digital Platform, an open cloud-based platform that supports the secure collection and analysis of health and lifestyle data from multiple sources and devices. Designed to support population health management, CareSage utilizes Philips Lifeline’s AutoAlert technology and wealth of aging and health data to focus on senior patients when they return home after a hospital visit or home health care period.

“Coming home after a hospital stay is a relief for seniors, but it also comes with potential risks. By reviewing data from CareSage’s analytics and our wearable medical alert devices, health systems can predict when their at-home patients are likely to be hospitalized and intervene in advance,” said Kimberly O’Loughlin, senior vice president and general manager of home monitoring, Philips. “CareSage is another example of Philips’ commitment to connected health; leveraging data, analytics and our 24x7 service monitoring capabilities to help provide health systems with the right data at the right time to help deliver care for a wide range of patient populations.”
 
Today, seniors use more health care resources per capita than any other group, and two-thirds of Medicare recipients are dealing with more than one chronic condition. Poor transitions in care are a key cause of unnecessary readmissions, emergency department visits and hospitalizations for seniors, which lead to both health and cost concerns. Health systems are looking to provide better outcomes at lower costs by extending care into the home, where many seniors’ health events occur. At the same time, while fewer than half of people who own wearable devices and fitness trackers actually use them every day, seniors have been active consumers of wearables for years in the form of medical alert services. When combined with predictive analytics, wearables for seniors can have a dramatic impact in proactively managing their health.
 
“More than half of frail and elderly patients are discharged without any long-term monitoring, leaving them cut off from their care while at home. Staying connected with these patients in between check-ups can help keep them healthy and help prevent events that could send them back to the hospital, which is our ultimate goal in patient care,” said Michael Hamaker, president, WellSpan VNA Home Care.
 
CareSage’s combines predictive analytics and senior-friendly home monitoring management and service tools already actively used by many consumers. Leveraging CareSage, health systems may be able to provide better preventative care and care coordination; increase patient satisfaction and improve quality of life issues; reduce long-term (beyond 30 days) avoidable readmissions; and improve health outcomes and cost savings.
 
Philips Lifeline is partnering with health systems to develop additional programs and applications for the predictive analytics engine.
 
For more information: www.healthcare.philips.com
 

Related Content

FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019
AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.

News | Heart Failure | September 12, 2019
Corvia Medical has sponsored and is actively enrolling patients in a heart failure (HF) device trial that, in addition...
 Tiny Wearable Cameras May Improve Quality of Life in Heart Failure Patients

Image courtesy of Amazon.com

News | Heart Failure | September 11, 2019
The ever-present devices that seem to track all our moves can be annoying, intrusive or worse, but for heart failure...
PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019
The angiotensin neprilysin inhibitor sacubitril/valsartan (Entresto) missed its primary endpoint of reducing total...
Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure
News | Heart Failure | September 09, 2019
AstraZeneca announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga (dapagliflozin) on...
Dapagliflozin, Forxiga, was found to help improve outcomes in heart failure patients with reduced ejection fraction (HFrEF) at ESC 2019. #ESC19 #ESC2019
News | Heart Failure | September 09, 2019
September 9, 2019 — The drug Dapagliflozin was found to reduce death and hospitalization in patients who have heart f
Entresto Improved Measures of Heart Structure and Function in Heart Failure Patients
News | Heart Failure | September 04, 2019
September 4, 2019 – Novartis announced results from two new...
FDA Approves Barostim Neo System for Advanced Heart Failure Patients. Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels.

Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels and inhibit the production of stress-related hormones to reduce heart failure symptoms.

Technology | Heart Failure | August 19, 2019
The U.S. Food and Drug Administration (FDA) approved the Barostim Neo System for the improvement of symptoms in...
Ancora Heart Enrolls First Patient in European Multi-center Study of AccuCinch Heart Failure Therapy
News | Heart Failure | August 14, 2019
Ancora Heart Inc. announced the first patient was enrolled in the CorCinch EU study, a European multi-center clinical...
Procyrion Receives FDA Breakthrough Device Designation for Aortix System
Technology | Heart Failure | July 30, 2019
Procyrion Inc. secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its Aortix...
Overlay Init